Tiziana Life Sciences announces that patient enrollment has been completed in its randomized, double-blind, placebo-controlled Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosi

[출처/시간] Briefing.com - 11:01 AM ET, 05/21/2026

Topline data is expected in late Q3 of 2026, and will also to be presented at
the 10th joint Americas Committee for Treatment and Research in
Multiple Sclerosis and ECTRIMS meeting in Toronto, Canada in October 2026.The trial, known as INFORM-MS, is the first Phase 2 placebo-controlled study of
intranasal foralumab, marking a significantmilestone in the clinical development of
this novel anti-CD3 monoclonal antibody for
neurodegenerative and neuroinflammatory diseases. The multicenter study has
enrolled 48 patients across multiple leading U.S. sites to receive one of two doses of intranasal
foralumab or placebo over a 12-week treatment period, with assessments including
PET imaging for microglial activation, MRI, clinical evaluations, and
biomarkers. Following the completion of the blinded phase, all participants
including those who initially received placebo will have the opportunity to
receive intranasal foralumab during a six-month open label extension phase. The OLE is
designed to assess long term safety and sustained benefit of foralumab in the
na-SPMS patient population.